Aa
ANY BODY OUT THER SMOKES CANNIBUS
IF YOU SMOKE CANNIBUS TO RELEAVE PAIN LEAVE A MESSAGE
"Results: Seventeen of the 71 study patients (24%) discontinued therapy early, one cannabis user (5%) and 16 non-users (33%)"
LOL to that. What? 16 non-users and only 1 user? Go figure... Poor schmucks probably opted out as soon as they could tell they were getting the placebo. The one user guy probably got hit by a semi in the middle of the study. j/k
I don't smoke pot because it doesn't work for me. Tried it a few times in college (hey, it was research) and always with the same effect, paranoia, anxiety and depression. Kind of the opposite reaction that one would hope for with that activity. So, safe to say since it made me miserable at college keg parties, it wouldn't be of any use to me in this application either.
I don't think its necessarily a gateway drug though and I've never seen good grounds for making it illegal. I find the above study showing the correlation with increased liver issues for hep-c'rs who smoke pot compelling though. The study would definitely give me pause If I was a toker - I would at least do more research before deciding to use while on tx.
LOL to that. What? 16 non-users and only 1 user? Go figure... Poor schmucks probably opted out as soon as they could tell they were getting the placebo. The one user guy probably got hit by a semi in the middle of the study. j/k
I don't smoke pot because it doesn't work for me. Tried it a few times in college (hey, it was research) and always with the same effect, paranoia, anxiety and depression. Kind of the opposite reaction that one would hope for with that activity. So, safe to say since it made me miserable at college keg parties, it wouldn't be of any use to me in this application either.
I don't think its necessarily a gateway drug though and I've never seen good grounds for making it illegal. I find the above study showing the correlation with increased liver issues for hep-c'rs who smoke pot compelling though. The study would definitely give me pause If I was a toker - I would at least do more research before deciding to use while on tx.
Makes me feel like singing a bit of "Hey 19" by Steely Dan:
The Cuervo Gold,
The fine Co-lum-bian
Make tonight a wonderful thing!
The Cuervo Gold,
The fine Co-lum-bian
Make tonight a wonderful thing!
Just hold the Cuervo, please!
The Cuervo Gold,
The fine Co-lum-bian
Make tonight a wonderful thing!
The Cuervo Gold,
The fine Co-lum-bian
Make tonight a wonderful thing!
Just hold the Cuervo, please!
Puff Puff Give. PUFF PUFF GIVE!!! (just kidding)
Cannabis use hastens short term memory loss and lowers comprehension levels. I wager, while under the influence, 90% of cannabis users could not remember or comprehend 10% of the abstract posted by lost39.
I know some on tx have no appetite and marijuana can stimulate appetite and keep people on tx. This is a good thing. However, just like the tx we're on, the long term side affects can be worse than what we are treating.
Grandma,
Drug/Alcohol use and abuse has negatively shaped the lives of some of my family members and friends. Marijuana can DEFINITELY be a gateway.
Cannabis use hastens short term memory loss and lowers comprehension levels. I wager, while under the influence, 90% of cannabis users could not remember or comprehend 10% of the abstract posted by lost39.
I know some on tx have no appetite and marijuana can stimulate appetite and keep people on tx. This is a good thing. However, just like the tx we're on, the long term side affects can be worse than what we are treating.
Grandma,
Drug/Alcohol use and abuse has negatively shaped the lives of some of my family members and friends. Marijuana can DEFINITELY be a gateway.
One thing not addressed in any study is any possible negative interaction between cannabis and IFN/Riba. Can Cannabis reduce the efficacy of IFN/Riba ? No one knows at this point. Drug interactions between approved pharmaceuticals and IFN/Riba are not fully known, let alone botanicals.
For those who feel there is no reason to worry about possible interactions they should be reminded of a deadly connection between a botanical and a pharmaceutical which occurred in recent history. No one knows exactly how many HIV/AIDS sufferers went to an early grave because they used St John's Wort for depression. Taking this was a very popular practice amongst the HIV/AIDS community for quite awhile. After a decade it was discovered that St John's reduced the efficacy of one of the most important drugs in use at the time. Practically rendered it useless. Natural does not mean safe.
A license to grow in the USA isn't worth the paper its written on in the eyes of the federal gov't . State law never supercedes federal law , so if they want to , you can be busted. It has happened to several "license" holders here. They don't actively seek out MM users, but arrests have occurred nationwide in states where it is legal under state statute. Don't feel 100% insulated because you paid a fee to the state.
Treatment was so difficult for me that I couldn't see doing (or taking) anything that could possibly have a negative impact on the outcome. But , I also think that If it takes a toke or two a day to keep you on tx it may be worth it I think one could make a plausible argument for its use in this scenario.
Mr Liver
For those who feel there is no reason to worry about possible interactions they should be reminded of a deadly connection between a botanical and a pharmaceutical which occurred in recent history. No one knows exactly how many HIV/AIDS sufferers went to an early grave because they used St John's Wort for depression. Taking this was a very popular practice amongst the HIV/AIDS community for quite awhile. After a decade it was discovered that St John's reduced the efficacy of one of the most important drugs in use at the time. Practically rendered it useless. Natural does not mean safe.
A license to grow in the USA isn't worth the paper its written on in the eyes of the federal gov't . State law never supercedes federal law , so if they want to , you can be busted. It has happened to several "license" holders here. They don't actively seek out MM users, but arrests have occurred nationwide in states where it is legal under state statute. Don't feel 100% insulated because you paid a fee to the state.
Treatment was so difficult for me that I couldn't see doing (or taking) anything that could possibly have a negative impact on the outcome. But , I also think that If it takes a toke or two a day to keep you on tx it may be worth it I think one could make a plausible argument for its use in this scenario.
Mr Liver
thanks for the vote of confidence...whatever gets us thru the the nite/mare of trx and onto SVR is alright with me..so sorry about yr husbands situation..wasn't he working as mason on movie projects last yr? i consider that a supreme test of strength(both of character&body) and a testamnt to his love of independence& family devotion..in short,a GREAT man...my regards and my hardhats off to both of you...my best to you&yours..
I guess a person can find a study somewhere to support just about anything. This study uses the same reference as the one above.....
"D L Sylvestre, B J Clements, Y Malibu. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18(10): 1057-1063. October 2006".
Daily Cannabis Use Increases Risk of Liver Fibrosis in People with Hepatitis C
By Liz Highleyman
A recently published study found that medicinal use of cannabis can relieve side effects and help chronic hepatitis C patients stay on interferon-based therapy, thereby improving their chances of achieving sustained virological response.
However, based on other prior research, there is concern that frequent, heavy cannabis use may promote the development of liver fibrosis.
At the 57th annual meeting of the American Association for the Study of Liver Diseases, held last month in Boston, researchers from the University of California at San Francisco reported on a study looking at the association between cannabis use and severity of fibrosis in individuals with chronic hepatitis C virus (HCV) infection.
Between 2001 and 2004, the researchers interviewed 204 HCV-infected subjects enrolled through university and community sources, assessing demographics, risk factors for HCV, and use of cannabis and alcohol. Participants also received virological testing and liver biopsies, which were scored using the Ishak system (stages F0 to F6, from absent to severe fibrosis).
Results
A majority of participants (69%) were men, 49% were Caucasian, 21% were coinfected with HIV, most were low income, the median age was about 47 years, and for 70% the presumed route of infection was injection drug use.
The median lifetime duration and average daily use of alcohol were 29.1 years and 1.94 drink equivalents per day.
13.7% of subjects reported daily cannabis use within 12 months prior to enrollment, while 45.1% reported occasional use and 41.2% said they never used cannabis.
Fibrosis stage was as follows:
- F0 (absent): 27.5%;
- F1-F2 (minimal/mild): 55.4%;
- F3-F6 (moderate to severe): 17.2%.
Daily cannabis use (compared with occasional or no use) was strongly associated with moderate to severe fibrosis by univariate analysis (odds ratio [OR] 3.21; P = 0.020).
The same held true by multivariate analyses (OR 6.78; P = 0.003).
Other independent predictors of moderate to severe fibrosis were:
- lifetime duration of moderate to heavy alcohol use (> 2 and > 4 drinks per day in women and men, respectively; OR 1.72 per 10 years; P = 0.044)
- > 11 portal tracts (compared to 11 portal tracts (compared to < 5) (OR 3.43, P = 0.002 and OR 10.4, P < 0.001, respectively);
Patient sex, race, age, duration of HCV infection, HCV genotype, HIV status, body weight, tobacco use, and lifetime alcohol use were not significantly associated with mild fibrosis in this study.
Conclusion
"Current daily cannabis use independently increased the odds of moderate to severe fibrosis by nearly 7-fold in persons with chronic HCV infection," the researchers concluded. "Our results indicate that HCV-infected individuals should be counseled to reduce or abstain from cannabis use."
11/14/06
References
J H Ishida, C Jin, P Bacchetti, and others. Influence of Cannabis Use on Severity of Hepatitis C Disease. 57th AASLD. Boston, MA. October 27-31, 2006. Abstract 211.
D L Sylvestre, B J Clements, Y Malibu. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18(10): 1057-1063. October 2006.
"D L Sylvestre, B J Clements, Y Malibu. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18(10): 1057-1063. October 2006".
Daily Cannabis Use Increases Risk of Liver Fibrosis in People with Hepatitis C
By Liz Highleyman
A recently published study found that medicinal use of cannabis can relieve side effects and help chronic hepatitis C patients stay on interferon-based therapy, thereby improving their chances of achieving sustained virological response.
However, based on other prior research, there is concern that frequent, heavy cannabis use may promote the development of liver fibrosis.
At the 57th annual meeting of the American Association for the Study of Liver Diseases, held last month in Boston, researchers from the University of California at San Francisco reported on a study looking at the association between cannabis use and severity of fibrosis in individuals with chronic hepatitis C virus (HCV) infection.
Between 2001 and 2004, the researchers interviewed 204 HCV-infected subjects enrolled through university and community sources, assessing demographics, risk factors for HCV, and use of cannabis and alcohol. Participants also received virological testing and liver biopsies, which were scored using the Ishak system (stages F0 to F6, from absent to severe fibrosis).
Results
A majority of participants (69%) were men, 49% were Caucasian, 21% were coinfected with HIV, most were low income, the median age was about 47 years, and for 70% the presumed route of infection was injection drug use.
The median lifetime duration and average daily use of alcohol were 29.1 years and 1.94 drink equivalents per day.
13.7% of subjects reported daily cannabis use within 12 months prior to enrollment, while 45.1% reported occasional use and 41.2% said they never used cannabis.
Fibrosis stage was as follows:
- F0 (absent): 27.5%;
- F1-F2 (minimal/mild): 55.4%;
- F3-F6 (moderate to severe): 17.2%.
Daily cannabis use (compared with occasional or no use) was strongly associated with moderate to severe fibrosis by univariate analysis (odds ratio [OR] 3.21; P = 0.020).
The same held true by multivariate analyses (OR 6.78; P = 0.003).
Other independent predictors of moderate to severe fibrosis were:
- lifetime duration of moderate to heavy alcohol use (> 2 and > 4 drinks per day in women and men, respectively; OR 1.72 per 10 years; P = 0.044)
- > 11 portal tracts (compared to 11 portal tracts (compared to < 5) (OR 3.43, P = 0.002 and OR 10.4, P < 0.001, respectively);
Patient sex, race, age, duration of HCV infection, HCV genotype, HIV status, body weight, tobacco use, and lifetime alcohol use were not significantly associated with mild fibrosis in this study.
Conclusion
"Current daily cannabis use independently increased the odds of moderate to severe fibrosis by nearly 7-fold in persons with chronic HCV infection," the researchers concluded. "Our results indicate that HCV-infected individuals should be counseled to reduce or abstain from cannabis use."
11/14/06
References
J H Ishida, C Jin, P Bacchetti, and others. Influence of Cannabis Use on Severity of Hepatitis C Disease. 57th AASLD. Boston, MA. October 27-31, 2006. Abstract 211.
D L Sylvestre, B J Clements, Y Malibu. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18(10): 1057-1063. October 2006.
no dea here and i really like all the resposes my research is all personal during the first 8 weeks was hell didnt really expect to get so sick i was 50 then all the symptons hit me i was allready skinny and couldnt loss any more weight so i smoked 3 joints every day for the first year and finished my treatment. some times i think to my self maybe if ididnt smoke those joints may be my treatment would of worked i continued and started my second regerment i felt that i could finish my treatment without smoking any joints during the first few weeks the treatment wasnt working but i finished the scond regement and gave my liver a rest im 55 now and i decided what the hell smoking joints makes me feal good
Yes, I will 2nd that reputable. How are you. I should come free too, I also used pot thru tx and it did help with sides and appetite. I am now9 months post UND. I can relate to tx and sides. Every one has their own opinion on things. Right now my husband cannot put on weight and has no appetite. It is hard to get him to eat. He now has his license to cannabis. Helps a great deal, not what I want to see him eat but enough to keep him alive.
Cajun
Cajun
i used pot during trx to reduce the sx's of trx drugs,improve my sense of humor and increase appetite...i am SVR now and just an ocassional puffer,but during trx a hit every day made it all seem more bearable-just one man's experience..oh,i am considered fairly reputable herebouts!
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.
Original Articles
European Journal of Gastroenterology & Hepatology. 18(10):1057-1063, October 2006.
Sylvestre, Diana L. a b; Clements, Barry J. b; Malibu, Yvonne b
Abstract:
Objectives: Despite the widespread use of polypharmacy, the management of hepatitis C virus (HCV) treatment-related side-effects is often incomplete, and many patients turn to cannabis for symptom relief. Unfortunately, there are few data about cannabis use on treatment outcomes, leaving clinicians without the data needed to inform recommendations.
Methods: To define the impact of cannabis use during HCV treatment, we conducted a prospective observational study of standard interferon and ribavirin treatment in 71 recovering substance users, of whom 22 (31%) used cannabis and 49 (69%) did not.
Results: Seventeen of the 71 study patients (24%) discontinued therapy early, one cannabis user (5%) and 16 non-users (33%) (P=0.01). Overall, 37 patients (52%) were end-of-treatment responders, 14 (64%) cannabis users and 23 (47%) non-users (P=0.21). A total of 21 out of 71 (30%) had a sustained virological response: 12 of the 22 cannabis users (54%) and nine of the 49 non-users (18%) (P=0.009), corresponding to a post-treatment virological relapse rate of 14% in the cannabis users and 61% in the non-users (P=0.009). Overall, 48 (68%) were adherent, 29 (59%) non-users and 19 (86%) cannabis users (P=0.03). Although cannabis users were no more likely than non-users to take at least 80% of the prescribed interferon or ribavirin, they were significantly more likely to remain on HCV treatment for at least 80% of the projected treatment duration, 95 versus 67% (P=0.01).
Conclusions: Our results suggest that modest cannabis use may offer symptomatic and virological benefit to some patients undergoing HCV treatment by helping them maintain adherence to the challenging medication regimen.
Original Articles
European Journal of Gastroenterology & Hepatology. 18(10):1057-1063, October 2006.
Sylvestre, Diana L. a b; Clements, Barry J. b; Malibu, Yvonne b
Abstract:
Objectives: Despite the widespread use of polypharmacy, the management of hepatitis C virus (HCV) treatment-related side-effects is often incomplete, and many patients turn to cannabis for symptom relief. Unfortunately, there are few data about cannabis use on treatment outcomes, leaving clinicians without the data needed to inform recommendations.
Methods: To define the impact of cannabis use during HCV treatment, we conducted a prospective observational study of standard interferon and ribavirin treatment in 71 recovering substance users, of whom 22 (31%) used cannabis and 49 (69%) did not.
Results: Seventeen of the 71 study patients (24%) discontinued therapy early, one cannabis user (5%) and 16 non-users (33%) (P=0.01). Overall, 37 patients (52%) were end-of-treatment responders, 14 (64%) cannabis users and 23 (47%) non-users (P=0.21). A total of 21 out of 71 (30%) had a sustained virological response: 12 of the 22 cannabis users (54%) and nine of the 49 non-users (18%) (P=0.009), corresponding to a post-treatment virological relapse rate of 14% in the cannabis users and 61% in the non-users (P=0.009). Overall, 48 (68%) were adherent, 29 (59%) non-users and 19 (86%) cannabis users (P=0.03). Although cannabis users were no more likely than non-users to take at least 80% of the prescribed interferon or ribavirin, they were significantly more likely to remain on HCV treatment for at least 80% of the projected treatment duration, 95 versus 67% (P=0.01).
Conclusions: Our results suggest that modest cannabis use may offer symptomatic and virological benefit to some patients undergoing HCV treatment by helping them maintain adherence to the challenging medication regimen.
Could you post some reputable sources other than "many think" or "some say". I am not down on pot. I am all about facts though. If pot use is a benefit to someone with HCV whether treating or not I would really like to know.
I am sorry for your family' s suffering. I would amend your statement to it CAN be a gateway drug. Icecream can be a gateway to overeating, for some, not for all.
Even if I should get glaucoma I will not smoke it. It ruined half my family and my first marriage. It is a gateway drug.
I have a script for this helpful herb. Many think its better than using the pharmacueticals for helping with side effects.
Research money is available to show its down sides, only . Some say. . .
Research money is available to show its down sides, only . Some say. . .
woooo hoooo let's smoke a joint drink a 40 ouncer and have a party - I'll bring the liver pate LOL
they just keep coming don't they
I have a feling chevy is penning these drug and alcohol posts
they just keep coming don't they
I have a feling chevy is penning these drug and alcohol posts
It is actually none of my business what anyone does as long as they don't harm others. But for those that are interested in their health, the following article may be of interest:
April 11 - 15, 2007, Barcelona, Spain
THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Cannabis Use Predicts Severe Liver Steatosis in Patients with Chronic Hepatitis C
By Liz Highleyman
A study reported in October 2006* showed that modest use of medicinal cannabis may benefit some patients undergoing treatment for chronic hepatitis C by helping them maintain adherence to combination therapy.
However, some experts expressed concern about hepatitis C patients using cannabis, since a French study of untreated individuals with HCV showed that those who used marijuana daily were more likely to have severe liver fibrosis, and were at higher risk for rapid fibrosis progression, than those who used marijuana only occasionally or not at all.**
At the recent 42nd Annual Meeting of the European Association for the Study of the Liver in Barcelona, Spain, the same research team reported on a study of the link between cannabis use and liver steatosis.
As background, the researchers noted that Cannabis sativa binds to 2 receptors, CB1 and CB2, and recent experimental data suggest that activation of CB1 receptors increases steatogenesis (fat accumulation).
The present study included 311 consecutive treatment-naive patients with histologically proven chronic hepatitis C. The investigators collected epidemiological data; clinical data including body mass index (BMI), diabetes, serum fasting glucose, triglycerides, and cholesterol levels; and recorded intake of cannabis, alcohol, tobacco, and maintenance treatment over the semester preceding liver biopsy. Degrees of steatosis, fibrosis (METAVIR), and histological activity were assessed by 2 pathologists without knowledge of clinical data; marked steatosis was defined as > 30% of hepatocytes.
Results
Patients (220 men, 91 women, mean age 45 years) were grouped according to frequency of cannabis use:
non-users (59%);
occasional users (less than 1 joint daily): 15%, median 4 joints per month;
daily users (at least 1 joint daily): 26%, median 75 joints per month.
In an unadjusted analysis, marked steatosis was associated with frequency of cannabis use, as follows:
16.3% in non-users;
10.9% in occasional users;
30.9% in daily users (P=0.006).
Marked steatosis was also associated with:
BMI >27 kg/m2 (29.5% vs 15.9%, P=0.008);
use of maintenance treatment (39.1% vs 17.7%, P=0.01);
alcohol consumption of 30 g/day or more (35.7% vs 16.7%, P=0.004);
genotype 3 HCV (40.0% vs 13.9%, P<0.001);
hyperglycemia (50.0% versus 20.0%, P<0.001)
histological activity grade A2 or higher (25.4% vs 10.8%, P=0.001);
fibrosis stage F2 or higher (29.1% vs 13.9%, P=0.003).
In a multivariate analysis, independent predictors of marked steatosis were:
daily cannabis use (OR=2.13);
histological activity grade A2 or higher (OR=2.40);
genotype 3 HCV (OR=4.41);
hyperglycemia (OR=6.83).
Conclusion
In conclusion, the investigators wrote, “this study discloses a strong link between daily cannabis use and steatosis severity in patients with chronic hepatitis C and supports recent experimental data demonstrating steatogenic effects of CB1 receptors.”
They added that, “These observations, and our previous results showing that daily cannabis smoking is also an independent predictor of fibrosis progression, indicate that patients with untreated chronic hepatitis C should be advised to refrain from daily cannabis use.
Department of Hepatology, Hopital Henri Mondor; INSERM U635, Hopital Henri Mondor; Department of Patology, Hopital Henri Mondor; Department of Public Health, Hopital Henri Mondor; Department of Virology, Hopital Henri Mondor; INSERM U581, Hopital Henri Mondor, Creteil, France.
04/24/07
References
C Hezode, ES Zafrani, F Roudot-Thoraval, and others. Cannabis use as an independent predictor of severe steatosis during chronic hepatitis C. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain. April 11-15, 2007.
*DL Sylvestre, BJ Clements, Y Malibu. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18(10): 1057-1063. October 2006.
**C Hezode, F Roudot-Thoraval, S Nguyen, and others. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42(1): 63-71. July 2005.
April 11 - 15, 2007, Barcelona, Spain
THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Cannabis Use Predicts Severe Liver Steatosis in Patients with Chronic Hepatitis C
By Liz Highleyman
A study reported in October 2006* showed that modest use of medicinal cannabis may benefit some patients undergoing treatment for chronic hepatitis C by helping them maintain adherence to combination therapy.
However, some experts expressed concern about hepatitis C patients using cannabis, since a French study of untreated individuals with HCV showed that those who used marijuana daily were more likely to have severe liver fibrosis, and were at higher risk for rapid fibrosis progression, than those who used marijuana only occasionally or not at all.**
At the recent 42nd Annual Meeting of the European Association for the Study of the Liver in Barcelona, Spain, the same research team reported on a study of the link between cannabis use and liver steatosis.
As background, the researchers noted that Cannabis sativa binds to 2 receptors, CB1 and CB2, and recent experimental data suggest that activation of CB1 receptors increases steatogenesis (fat accumulation).
The present study included 311 consecutive treatment-naive patients with histologically proven chronic hepatitis C. The investigators collected epidemiological data; clinical data including body mass index (BMI), diabetes, serum fasting glucose, triglycerides, and cholesterol levels; and recorded intake of cannabis, alcohol, tobacco, and maintenance treatment over the semester preceding liver biopsy. Degrees of steatosis, fibrosis (METAVIR), and histological activity were assessed by 2 pathologists without knowledge of clinical data; marked steatosis was defined as > 30% of hepatocytes.
Results
Patients (220 men, 91 women, mean age 45 years) were grouped according to frequency of cannabis use:
non-users (59%);
occasional users (less than 1 joint daily): 15%, median 4 joints per month;
daily users (at least 1 joint daily): 26%, median 75 joints per month.
In an unadjusted analysis, marked steatosis was associated with frequency of cannabis use, as follows:
16.3% in non-users;
10.9% in occasional users;
30.9% in daily users (P=0.006).
Marked steatosis was also associated with:
BMI >27 kg/m2 (29.5% vs 15.9%, P=0.008);
use of maintenance treatment (39.1% vs 17.7%, P=0.01);
alcohol consumption of 30 g/day or more (35.7% vs 16.7%, P=0.004);
genotype 3 HCV (40.0% vs 13.9%, P<0.001);
hyperglycemia (50.0% versus 20.0%, P<0.001)
histological activity grade A2 or higher (25.4% vs 10.8%, P=0.001);
fibrosis stage F2 or higher (29.1% vs 13.9%, P=0.003).
In a multivariate analysis, independent predictors of marked steatosis were:
daily cannabis use (OR=2.13);
histological activity grade A2 or higher (OR=2.40);
genotype 3 HCV (OR=4.41);
hyperglycemia (OR=6.83).
Conclusion
In conclusion, the investigators wrote, “this study discloses a strong link between daily cannabis use and steatosis severity in patients with chronic hepatitis C and supports recent experimental data demonstrating steatogenic effects of CB1 receptors.”
They added that, “These observations, and our previous results showing that daily cannabis smoking is also an independent predictor of fibrosis progression, indicate that patients with untreated chronic hepatitis C should be advised to refrain from daily cannabis use.
Department of Hepatology, Hopital Henri Mondor; INSERM U635, Hopital Henri Mondor; Department of Patology, Hopital Henri Mondor; Department of Public Health, Hopital Henri Mondor; Department of Virology, Hopital Henri Mondor; INSERM U581, Hopital Henri Mondor, Creteil, France.
04/24/07
References
C Hezode, ES Zafrani, F Roudot-Thoraval, and others. Cannabis use as an independent predictor of severe steatosis during chronic hepatitis C. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain. April 11-15, 2007.
*DL Sylvestre, BJ Clements, Y Malibu. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18(10): 1057-1063. October 2006.
**C Hezode, F Roudot-Thoraval, S Nguyen, and others. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42(1): 63-71. July 2005.
hey, just joking with you, maybe someone will come along to answer your question in a more legitimate way, I myself am not opposed to medical mj use, but can't use the stuff myself, gives me panic attacks from hell!
you with the DEA or somethin??? lol...just making a little funny...really little as it turns out:)
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
